Isofol Medical AB Advances Arfolitixorin Development Amid Financial Strategies

Isofol Medical AB ( (SE:ISOFOL) ) just unveiled an update.

Isofol Medical AB reported significant progress in the first quarter of 2025, particularly with its drug candidate arfolitixorin. The company received approval from German authorities to begin a clinical study with an optimized dosing regimen for metastatic colorectal cancer, and the first patient has already been treated. Additionally, Isofol’s Japanese partner, Solasia Pharma K.K., has committed to conducting and financing upcoming trials in Japan, reflecting strong confidence in arfolitixorin’s potential. Despite a net revenue of zero, the company is moving forward with a fully guaranteed rights issue to raise approximately SEK 85 million, subject to approval at an extraordinary general meeting.

More about Isofol Medical AB

Isofol Medical AB is a biotechnology company focused on improving the quality of life and prognosis for patients with severe forms of cancer. The company’s primary product, arfolitixorin, is a drug candidate aimed at enhancing the effectiveness of first-line standard treatments for several solid tumors, particularly in colorectal cancer, which is the third most common cancer globally. Isofol Medical AB is publicly traded on Nasdaq Stockholm.

Average Trading Volume: 374,872

Current Market Cap: SEK226M

See more insights into ISOFOL stock on TipRanks’ Stock Analysis page.